Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label drug-drug interaction study of JNJ-39393406 with midazolam in healthy male subjects
NL-OMON33240Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of JNJ-39393406 and midazolam in schizophrenia and Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Effect of single and multiple doses of JNJ-39393406 on midazolam pharmacokinetics. Started Jul 2009; status: active, not recruiting.
02
Drugs
JNJ-39393406midazolam
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON33240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33240.